Creativity
Few beliefs about psychedelics are more widely held than that they unlock creativity, and few are less supported by controlled evidence. The cultural prior is enormous, artists, inventors and technologists have long credited these drugs with creative breakthroughs, but when researchers measure creativity properly, double-blind and against a placebo, the effect mostly evaporates. The most reliable finding in the whole literature is a dissociation: people feel markedly more creative while their measured performance is unchanged or, on some tasks, worse. Acute doses tend to raise novelty while lowering usefulness and impairing the kind of focused thinking that turns a wild idea into a finished one. Microdosing fares no better, beating placebo on essentially nothing. This page is about that gap between a powerful, sincere experience of creativity and the stubborn difficulty of showing it on a test.
Data updated
Key Insights
- 1
This is a theme page about a famous claim, not a condition or a treatment. It asks whether psychedelics genuinely enhance creativity, divergent and convergent thinking, problem-solving and artistic output, or whether the belief outruns the evidence.
- 2
The belief vastly outruns the evidence. Controlled, double-blind studies of creativity are mostly null, narrow or mixed, and the field openly acknowledges it lacks a uniform definition of creativity and rigorous designs.
- 3
The most reliable finding is a dissociation between feeling and performing. People consistently feel more creative on a psychedelic, or on a microdose, while their measured performance on creativity tasks does not improve, and sometimes gets worse.
- 4
Acute doses can impair the useful half of creativity. Psychedelics tend to raise novelty and originality while lowering usefulness, and they reliably impair convergent thinking, the focused reasoning that turns a novel idea into a workable one. Novelty without usefulness is not the same as creativity.
- 5
Microdosing for creativity is essentially unsupported. Across blinded trials it does not beat placebo, with the sole exception of one narrow measure of original-response ratio; the felt creativity of a microdose is largely expectation.
By the numbers
- 4
- Trials tracked
- 88
- Papers tracked
- 204
- Trial participants
as of June 2026
as of June 2026
as of June 2026
About Creativity
Creativity is not a condition or a treatment; it is one of the oldest and most cherished claims made for psychedelics. The idea that these drugs open up new ways of thinking, dissolve mental ruts and spark original insight is woven through the culture, from artists and musicians to the Silicon Valley microdosing-for-innovation story. This page asks a simple, awkward question: when you actually measure it, does any of that hold up? The short answer is that the belief is enormous and the controlled evidence is thin, mixed, and often pointing the other way.
The difficulty starts with what "creativity" even means. Researchers usually split it into divergent thinking, generating many varied ideas, and convergent thinking, homing in on the single best or most useful one. Real creativity needs both: the wild generation and the disciplined selection. Most creativity tests measure proxies for these, and those proxies are imperfect stand-ins for the messy, real-world business of making something genuinely new and worthwhile. That measurement problem is not a footnote here; it is central to why the evidence is so unsatisfying.
The single most important idea to carry through this page is the gap between feeling creative and being more creative. The clearest, most repeated result in this literature is that psychedelics make people feel more creative without making them measurably so, and on some tasks they make performance worse. That dissociation is genuinely interesting, the felt experience is real and may matter, but it is not the same as the claim people usually mean. Much of the loudest version of this story comes from microdosing, where the controlled evidence is weakest, and it overlaps with claims about lasting personality and trait change that are similarly shaky.
Approach & Methods
Because there is no condition here, the relevant "evidence" is how creativity is measured under controlled conditions, and what those measurements show. The best-designed study is a placebo-controlled LSD trial that gave a full creativity battery near the peak of the experience. Its result captures the whole topic in miniature: LSD increased novelty, surprise and originality, while decreasing utility and convergent thinking[1]. In other words, it pushed thinking toward the strange and away from the useful, and it impaired the focused reasoning that creativity also requires. A separate DMT and harmine trial likewise impaired convergent thinking, especially in the sharpest reasoners[2].
The broader picture is no kinder to the popular claim. A scoping review of psilocybin found that macrodoses tended to impair cognition and creativity acutely, with post-acute effects largely null[3], and a meta-analysis across studies found no significant effect on the majority of creativity and cognition measures[4]. The field is candid about why: as one of the LSD studies put it, psychedelic creativity research lacks a uniform conceptualisation of creativity and methodologically rigorous designs[1]. So the "standard" understanding is that controlled studies do not show a reliable creativity benefit, and sometimes show acute impairment, however strongly people feel otherwise.
This report summarises what Blossom’s database shows about psychedelics and creativity. It is worth being clear what kind of page this is. It is not a condition page and not a treatment. It is about one of the most popular claims ever made for these drugs, that they unlock creativity, and about the uncomfortable gap between how strongly that is believed and how little the controlled evidence supports it.
A note before the evidence
This page is a research summary, not medical advice, and nothing here is a recommendation to take psychedelics, including for creative work. The honest message below is largely deflating: when creativity is measured properly, psychedelics do not reliably enhance it, and can impair parts of it. Read this as a corrective to an appealing but poorly supported belief, not as career advice.
The strongest finding: feeling versus performing
If there is one robust result in this literature, it is a dissociation. People on a psychedelic, or even a microdose, consistently feel more creative, while their measured creativity does not improve. The cleanest demonstrations come from microdosing. A multimodal LSD trial found no change on any creativity task even though participants felt more creative on dose days[1], and a home-based LSD study found transient felt creativity on dose days but no real change after six weeks[2]. A placebo-controlled psilocybin study went further, finding the acute subjective effects appeared only in people who correctly guessed they had taken the active dose[3], which points squarely at expectation rather than chemistry.
This dissociation is genuinely interesting, and it is not nothing: the felt experience of fluid, novel, connected thinking is real, vivid, and may matter for how people approach problems even if it does not move a test score. But it is crucial to be precise about what it is and is not. "I felt extraordinarily creative" is a true and meaningful report. "Psychedelics made me more creative" is a different, stronger claim about measurable output, and that is the one the evidence does not support.
Novelty up, usefulness down
When controlled studies do detect changes in thinking, they are double-edged in a way that undercuts the simple "more creative" story. The best LSD creativity trial found that the drug raised novelty, surprise and originality while lowering utility and impairing convergent thinking[4]. This matters because real creativity is not just novelty; it is novelty that is also useful, and it requires convergent thinking, the focused reasoning that selects and refines a good idea from many wild ones, just as much as it requires divergent generation. A DMT and harmine trial similarly impaired convergent thinking, most in the strongest reasoners[5].
So the picture that emerges from the lab is not "psychedelics make you more creative" but something stranger and more specific: they can push thinking toward the original and unusual while degrading the disciplined part that turns originality into something worthwhile. Whether that net trade is a creative gain depends entirely on what you are trying to do, and on a part of the process, selection and refinement, that these drugs seem to hinder rather than help.
Microdosing: the loudest claim, the emptiest evidence
Nowhere is the creativity claim louder than in microdosing, and nowhere is the controlled evidence emptier. Across blinded trials, microdosing does not beat placebo on creativity. The single survivor, from a mega-analysis pooling three controlled trials, was a small rise in one narrow measure, the ratio of original to total responses, with no effect on anything else[6]. A psilocybin microdose study found no creative or cognitive enhancement and even some drift toward impairment[3], and a broad review concluded that where microdosing creativity effects appear, they are confined to self-report[7]. The microdosing page covers this in more depth, but the creativity-specific verdict is stark: the practice most associated with creative enhancement has essentially failed to demonstrate it.
Why this is so hard to measure
Some of the uncertainty is genuine, and it cuts in the believers’ favour as well as against. Creativity is extraordinarily hard to measure. The standard laboratory tasks, listing unusual uses for a brick, finding the word that links three others, are thin proxies for the real thing, and researchers themselves note that these tests may not capture the facets of creativity that are anecdotally affected[1]. The field has no agreed definition of creativity and few rigorous designs, a limitation the studies state openly. So a fair-minded reader has to hold open the possibility that there is a real effect the current tools cannot see.
But this argument has to be used honestly, because "our instruments cannot detect it" is unfalsifiable, and it cannot be allowed to rescue a claim indefinitely. The weight of the controlled evidence, the meta-analytic null across creativity and cognition measures[8], the acute impairments, the microdosing nulls, points the same way, and the burden of proof sits with those asserting the effect, not those failing to find it. The measurement problem is a reason for humility, not a licence to assume the belief is true.
Reading this honestly
So how should you read the creativity story? As a powerful belief that the evidence does not, so far, support. The cultural conviction that psychedelics unlock creativity is one of the strongest in the field, and the controlled science is one of the weakest: mostly null, sometimes mixed, occasionally showing acute impairment of the focused thinking creativity needs. The most robust finding is a dissociation, people feel far more creative than they measurably are, and the felt experience, while real and worth respecting, is not the claim most people mean. There is honest room for doubt, because creativity is genuinely hard to measure and current tests may miss something. But that uncertainty should make us cautious in both directions, not confident in the romantic one. The most useful thing this literature offers an honest reader is a simple, deflating discipline: to separate the vivid feeling of creativity from the measurable fact of it, and to notice that, for now, the evidence supports the feeling far more than the fact.
Acute Effect Characterisation
Acute drug effects and evidence levels observed in Creativity research — characterisation, not therapeutic efficacy.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| LSD This matrix characterises the size of any RELIABLE creativity effect under controlled conditions, not subjective feelings and not efficacy. LSD acutely raises subjective creativity and novelty/originality, but lowers utility and impairs convergent thinking; at microdoses, people feel more creative while creativity tasks show no change versus placebo. Felt, not measured. | Small | Low | Low |
| Psilocybin Creativity-effect characterisation, not efficacy. Across blinded microdose trials psilocybin does not beat placebo; the only surviving signal is a narrow originality/fluency ratio in a 171-participant mega-analysis, with convergent thinking unaffected. Macrodoses tend to impair creative-task performance acutely. | Small | Low | Low |
| Ayahuasca Creativity-effect characterisation, not efficacy. The controlled evidence points to no benefit or to impairment: a DMT/harmine trial impaired convergent thinking, and a ceremony study found divergent thinking decreased afterwards. Sparse, naturalistic and expectancy-laden; included to mark the honest negative. | None | Very Low | Low |
LSD and Creativity
LSD is the compound most romantically linked to creativity, and it has the best controlled creativity study, which makes its results especially telling. Given near the peak of the experience, LSD increased novelty, surprise, originality and the "semantic distance" between ideas, while decreasing their utility and impairing convergent thinking[1]. This is a precise and revealing picture: LSD does change thinking, pushing it toward the unusual and associative, but it trades away usefulness and the ability to converge on a good answer, which are just as essential to real creativity.
At microdoses, the popular sweet spot for "creative work", the story is even flatter. A multimodal LSD microdose trial found no effect on any creativity task, even though participants reported feeling more creative on dosing days[2], and a home-based microdose study found the same: creativity felt higher on dose days but nothing had changed by the end of six weeks[3]. LSD, in short, reliably produces the feeling of creativity and unreliably, if at all, produces the measurable thing. That is the honest summary of the field’s most celebrated creative drug.
Psilocybin and Creativity
Psilocybin is the other compound at the centre of the creativity claim, especially in microdosing culture, and it has been tested in several double-blind trials, which is exactly why its story is so deflating. A controlled psilocybin microdose study found no enhancement of creativity or cognition, with the acute subjective effects appearing only in people who correctly guessed they had the active dose[1], pinning the felt effect on expectation. The most that survives rigorous pooling is narrow: a mega-analysis of three blinded trials found a small rise in one measure, the ratio of original responses, and nothing else[2].
Full doses do not rescue the claim either. The scoping review found macrodoses tended to impair creative performance during the acute experience[3], and the wider microdosing literature concludes that where creativity changes appear at all, they are confined to self-report rather than objective tasks[4]. The careful reading is that psilocybin, the poster compound for creative microdosing, has essentially no demonstrated effect on measured creativity, and that the vivid sense of enhanced creativity it can produce is, on the best evidence, largely expectation.
Research Outlook
The most useful research direction is methodological honesty: better creativity measures and designs that can tell feeling from performance. The field knows its tools are weak, the same studies that report null results note that laboratory creativity tasks may not capture the facets of creativity anecdotally affected[1], which is a fair point and also a double-edged one, since "our tests cannot detect it" is the kind of claim that can never be falsified. The genuine open question is whether there is a real creative effect that current measures miss, or whether the felt creativity is the whole phenomenon.
There are a couple of threads worth watching. One is the distinction between acute and post-acute windows: an integrative review suggested convergent thinking might actually rise in the days after dosing, once the acute disruption has passed[2], though on thin evidence. Another is the difference between performance and process, between scoring higher on a task and approaching problems differently. The honest outlook is modest: barring better measurement, the safest conclusion is that psychedelics change the experience of thinking far more than they improve its measurable creative output, and that the burden of proof sits firmly with the believers.
Industrial Landscape
The creativity claim is driven less by industry than by culture. There is no obvious drug to sell here, no inflammatory disease or depression endpoint, so the momentum comes from the wider story of psychedelics as engines of art, insight and innovation, amplified by the microdosing-for-productivity movement and by a long lineage of creative people crediting these drugs. Academic researchers, by contrast, have mostly served as the bearers of bad news, running the controlled studies that keep failing to confirm the romance. The corpus itself reflects the enthusiasm, with phenomenological and speculative pieces sitting alongside the sobering trials.
For an honest broker, creativity is a clean example of how powerful a cultural prior can be, and how stubbornly it survives contact with evidence. The responsible posture is neither to mock the belief nor to endorse it. The felt experience of expanded, novel, associative thinking is real and worth taking seriously, and it is possible that current tests miss something genuine. But the measured story is clear and should be stated plainly: controlled studies do not show that psychedelics make people more creative, they sometimes show the opposite acutely, and the strongest single finding is that people feel more creative than they perform. The most useful thing this literature offers is the discipline to keep "I felt incredibly creative" and "I produced more creative work" as separate claims, only one of which the evidence supports, and not the one most people assume.
Quick Indicators
Organisations
Search →Leiden University
Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.
Johns Hopkins University
The Centre for Psychedelic and Consciousness Research focuses on how psychedelics affect behavior, cognition, brain function, and biological health markers. They have been at the forefront of demonstrating the safety and efficacy of psychedelics for mental disorders, expanding their focus into psilocybin research across multiple mental health conditions, including smoking cessation, major depressive disorder, and cancer-related anxiety.
National Council of Scientific and Technical Research, Argentina
The National Council of Scientific and Technical Research (CONICET; Consejo Nacional de Investigaciones Científicas y Técnicas) is Argentina’s principal government agency for promoting science and technology, funding over 11,000 researchers and 10,000 doctoral students across a nationwide network of research institutes and centres. CONICET supported the NATMICRO study, a naturalistic observational investigation of the psychological and cognitive effects of self-administered psilocybin microdosing conducted in Argentina.
People
Search →Federico Cavanna
Researcher in psychedelic science / neuroscientific researcher (exact current title not confidently verified)
He is a coauthor on multiple widely cited studies on psilocybin microdosing, DMT, and psychedelic use, helping characterize subjective, behavioral, and cognitive effects of psychedelics.
Robin Murphy
Researcher at the University of Auckland School of Pharmacy
She is a coauthor on multiple human psychedelic studies spanning LSD microdosing, sleep, and psilocybin/escitalopram comparisons, making her part of the team contributing to the modern evidence base for psychedelic medicine.
Henrik Jungaberle
Dr. sc. hum., CEO and founder of the MIND Foundation; Head of Development at OVID Clinic Berlin
He is a prominent European psychedelic research and implementation figure contributing to psilocybin clinical trials, harm reduction, and healthcare integration work.
Michiel Van Elk
Associate Professor of Cognitive Psychology at Leiden University
Michiel van Elk is a prominent psychedelic science researcher known for rigorous, skeptical work on psilocybin, microdosing, expectancy effects, and the psychological mechanisms and risks of psychedelic experiences.
Kate Godfrey
Research Associate at Imperial College London’s Centre for Psychedelic Research
Kate Godfrey is notable for contributing to leading human psychedelic research on microdosing, neuroimaging, and neuroplasticity at Imperial College London.
Anna Forsyth
Doctoral researcher / researcher at the University of Auckland
She is an author on multiple clinical studies of LSD microdosing in depression and related psychedelic psychiatry work, contributing to early human evidence on efficacy, tolerability, and mechanism.
Frederick Sundram
Associate Professor and Deputy Head of the Department of Psychological Medicine at the University of Auckland
He is a psychiatrist and clinical researcher contributing to psychedelic and novel-antidepressant studies, including LSD microdosing and ketamine/depression research.
Valerie Bonnelle
Scientific Assistant to the Director at the Beckley Foundation
She is a researcher coordinating psychedelic studies on microdosing, pain, autonomic physiology, and peak experiences, contributing to the clinical and mechanistic understanding of psychedelic effects.
Laura Alethia de la Fuente
Postdoctoral researcher in neuroscience at CONICET / Instituto de Física de Buenos Aires (IFIBA-UBA)
She co-authored several notable human psychedelic studies on psilocybin microdosing, DMT, and acute psilocybin effects, contributing both behavioral and neurophysiological evidence in the field.
Heith Copes
Professor of Criminal Justice at the University of Alabama at Birmingham
Heith Copes is a criminologist whose research connects drug use, identity, and narrative meaning, including multiple collaborations on classic psychedelics, microdosing, and related social/behavioral outcomes.
Matthew Baggot
Neuroscientist and CEO of Tactogen
He is a leading MDMA/entactogen researcher whose work has helped characterize the drug’s effects on emotion, social behavior, and therapeutic potential in humans.
Lilian Kloft
PhD candidate / researcher at Maastricht University
She is a psychopharmacology and forensic psychology researcher contributing to human studies on ayahuasca, MDMA, memory, and psychedelic-related brain and cognitive effects.
Connected Evidence
The latest clinical data and verified academic findings associated with Creativity.